Evidence map›Paper›PMID 26736036›Full record

Trial reportJournal of psychiatric research2016

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.

Jeffery Newell, Jerome A Yesavage, Joy L Taylor, Helena C Kraemer, Cynthia A Munro, Leah Friedman, Paul B Rosenberg, Michelle Madore, Steven Z Chao, D P Devanand and 10 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychiatric research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Jeffery NewellDepartment of Psychology, University of Southern California, Los Angeles, CA, 90089, United States.
Jerome A YesavageDepartment of Veterans Affairs Health Care System, Palo Alto, CA, 94304, United States; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305-5717, United States; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, United States. Electronic address: yesavage@stanford.edu.
Joy L TaylorDepartment of Veterans Affairs Health Care System, Palo Alto, CA, 94304, United States; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305-5717, United States.
Helena C KraemerDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305-5717, United States.
Cynthia A MunroDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, 21205, United States.
Leah FriedmanDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305-5717, United States.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, 21205, United States.
Michelle MadoreDepartment of Veterans Affairs Health Care System, Palo Alto, CA, 94304, United States; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305-5717, United States.
Steven Z ChaoDepartment of Veterans Affairs Health Care System, Palo Alto, CA, 94304, United States; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, United States.
D P DevanandDivision of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY, 10032, United States; College of Physicians and Surgeons of Columbia University, New York, NY, 10032, United States.
Lea T DryeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States.
Jacobo E MintzerClinical Biotechnology Research Institute, Roper St. Francis Healthcare, Charleston, SC, 29401, United States; Ralph H. Johnson VA Medical Center, SC, 29401, United States.
Bruce G PollockCampbell Institute, CAMH, University of Toronto, Toronto, Ontario, M5S 2S1, Canada.
Anton P PorsteinssonUniversity of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, United States.
Lon S SchneiderUniversity of Southern California Keck School of Medicine, Los Angeles, CA, 90033, United States.
David M ShadeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States.
Daniel WeintraubPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States; Department of Veterans Affairs, Philadelphia, PA, 19104, United States.
Constantine G LyketsosDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, 21205, United States.
Art NodaDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305-5717, United States.
CitAD Research Group
Stanford University · USJohns Hopkins University · USJohns Hopkins Bayview Medical Center · USUniversity of Southern California · USVA Palo Alto Health Care System · USNew York Psychoanalytic Society and Institute · USRalph H. Johnson VA Medical Center · USUniversity of Pennsylvania · USUniversity of Rochester · USUniversity of Toronto · CA

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARANDA, MARIA P. · 1985 to 2019
$41.0M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
Citalopram Treatment for Agitation in Alzheimer DementiaR01AG031348 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 2008 to 2012
$7.9M
PTSD, Sleep-Disordered Breathing and APOE Genotype: Effects on CognitionI01CX000224 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI YESAVAGE, JEROME A · 2011 to 2014
–
CSRD VA I01 CX000224Intramural VA VA999999NIA NIH HHS NIH P50, AG05142NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG031348NIA NIH HHS R01AG031348
6 · The paper itself

Abstract

backgroundWe found a benefit of citalopram for agitation in the Citalopram for Agitation in Alzheimer's Disease study (CitAD), and wondered if this was mediated by a sedative effect. CitAD was a randomized, placebo-controlled, double-blind, parallel group trial conducted at 8 academic centers in the United States and Canada from August 2009 to January 2013. One hundred sixty-two participants with probable Alzheimer's disease (AD) and clinically significant agitation were analyzed in this study. Participants received a psychosocial intervention and were randomized to receive either citalopram or placebo (approximately half assigned to each group). Participants were rated on the Neurobehavioral Rating Scale Agitation subscale and measures of sedation (i.e., fatigue and somnolence).

methodsUsing the MacArthur Foundation procedures for documenting a mediator effect, we performed a secondary analysis examining whether sedation mediates the effect of treatment on agitation outcome.

resultsWe found a statistically significant mediating effect of sedation on agitation outcomes, but the magnitude of the effect was small, only explaining 11% of the variance in agitation, with a significant, but modest effect size of 0.16 (95% CI: 0.08 to 0.22).

conclusionsThe benefit of citalopram was partly due to sedation but largely due to other mechanisms of action.

Indexed as

Outcome Assessment, Health CareAlzheimer DiseaseCitalopramDouble-Blind MethodHumansHypnotics and SedativesPsychomotor AgitationSelective Serotonin Reuptake InhibitorsCitalopramHypnotics and SedativesSelective Serotonin Reuptake InhibitorsAgitationCitalopramSedation

Identifiers

PMID26736036
PMCPMC4744510
OpenAlexW2198210708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.